Imclone systems (IMCL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL)

IMCL 0.159

0.0%

Oct 5 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Abel Vieira who wrote (92)	5/4/1998 8:30:00 PM
From: Hardware Heister	Read Replies (2) of 2515

IMCL is similar to ENMD! Why is it not moving higher! The New York Times' cover story on Sunday mentioned only the other company, Entremed, and since most of Wall Street reads the NY Times Sunday edition, the stock took off. IMCL's C225 works by attacking the cancerous cells & is being tested in combo with other (chemotherapeutic) agents. Entremed's stuff basically shrinks tumors by cutting them off from their blood supply. It somehow shrinks the blood vessels down. It works by itself, and, at least in mice, targets only tumors. Assuming this translates directly to human trials (which doesn't always happen) Entremed's stuff is therefore more effective and has fewer side effects, since it doesn't require chemotherapeutic agents.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next